EnGene

About EnGene

enGene Holdings Inc. operates as a clinical-stage biotechnology company focused on developing genetic medicines. The firm is advancing a proprietary non-viral gene therapy platform for the localized delivery of various nucleic acid payloads to mucosal tissues and other organs.

The company's core technology is its Dually Derivatized Oligochitosan (DDX) platform. This system is engineered to penetrate mucosal tissues, enabling the delivery of a wide range of cargo types and sizes, including DNA and different forms of RNA. The DDX platform is designed to turn mucosal cells into localized 'factories' for producing therapeutic proteins and RNAs, creating a potent therapeutic effect while aiming to avoid the immunogenicity and systemic effects often associated with viral-based gene therapies.

enGene's lead product candidate is EG-70, also known as detalimogene voraplasmid. EG-70 is a non-viral immunotherapy being evaluated as a monotherapy for patients with non-muscle invasive bladder cancer (NMIBC) who have carcinoma in situ (CIS) and are unresponsive to Bacillus Calmette-Guérin (BCG) treatment. The company is conducting a Phase 2 pivotal study for EG-70 to address this high-need clinical area.

Co-founded by Dr. Anthony T. Cheung, who currently serves as the Chief Scientific Officer, the company leverages his expertise in its scientific development. On November 1, 2023, enGene completed a business combination with a special purpose acquisition company, Forbion European Acquisition Corp., which resulted in enGene Holdings Inc. becoming a publicly traded entity on the Nasdaq under the symbol 'ENGN'. This transaction provided gross proceeds of approximately $138.0 million to fund its operations and clinical trials. The company's business model is centered on research and development, strategic partnerships with pharmaceutical companies, and the eventual commercialization of its therapeutic products. Revenue streams are expected from licensing agreements, milestone payments, royalties, and direct product sales upon regulatory approval.